Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name IDRX-42
Synonyms
Therapy Description

IDRX-42 is a KIT inhibitor, which potentially decreases tumor cell viability and reduces tumor growth (PMID: 40018846).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
IDRX-42 M-4205|M 4205|M4205|IDRX 42|IDRX42 KIT Inhibitor 57 IDRX-42 is a KIT inhibitor, which potentially decreases tumor cell viability and reduces tumor growth (PMID: 40018846).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KIT V559D Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT V559D in an vitro assay (PMID: 40018846). 40018846
KIT T670I Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT T670I in an vitro assay (PMID: 40018846). 40018846
KIT D816F Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT D816F in an vitro assay (PMID: 40018846). 40018846
KIT D820E Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT D820E in an vitro assay (PMID: 40018846). 40018846
KIT D816V Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT D816V in an vitro assay (PMID: 40018846). 40018846
KIT D816E Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT D816E in an vitro assay (PMID: 40018846). 40018846
KIT D820Y Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT D820Y in an vitro assay (PMID: 40018846). 40018846
KIT W557_K558del Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT W557_K558del in an vitro assay (PMID: 40018846). 40018846
KIT W557_K558del gastrointestinal stromal tumor sensitive IDRX-42 Preclinical - Pdx Actionable In a preclinical study, IDRX-42 induced tumor regression in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_K558del (PMID: 40018846). 40018846
FLT3 exon 14 ins acute myeloid leukemia sensitive IDRX-42 Preclinical - Cell culture Actionable In a preclinical study, IDRX-42 inhibited viability of acute myeloid leukemia cell lines harboring FLT3-ITD in culture (PMID: 40018846). 40018846
KIT W557_K558del KIT V654A gastrointestinal stromal tumor sensitive IDRX-42 Preclinical - Pdx Actionable In a preclinical study, IDRX-42 treatment led to a complete response in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_K558del and KIT V654A (PMID: 40018846). 40018846
KIT V560G KIT D816V Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT V560G and KIT D816V in an vitro assay (PMID: 40018846). 40018846
KIT Y823D Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT Y823D in an vitro assay (PMID: 40018846). 40018846
KIT A829P Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT A829P in an vitro assay (PMID: 40018846). 40018846
KIT V560G Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT V560G in an vitro assay (PMID: 40018846). 40018846
KIT D816I Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT D816I in an vitro assay (PMID: 40018846). 40018846
KIT V559D KIT T670I Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT V559D and KIT T670I in an vitro assay (PMID: 40018846). 40018846
KIT W557Lfs*5 KIT P577del KIT D820G gastrointestinal stromal tumor predicted - sensitive IDRX-42 Preclinical - Pdx Actionable In a preclinical study, IDRX-42 treatment inhibited mitosis and decreased tumor growth in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT P577del, W557Lfs*5, and D820G (PMID: 37223931). 37223931
KIT V654A Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT V654A in an vitro assay (PMID: 40018846). 40018846
KIT V560_Y578del gastrointestinal stromal tumor sensitive IDRX-42 Preclinical - Cell line xenograft Actionable In a preclinical study, IDRX-42 inhibited viability of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture, and induced tumor regression in a cell line xenograft model (PMID: 40018846). 40018846
KIT W557_V559delinsF gastrointestinal stromal tumor sensitive IDRX-42 Preclinical - Pdx & cell culture Actionable In a preclinical study, IDRX-42 inhibited viability of a gastrointestinal stromal tumor cell line harboring KIT W557_V559delinsF in culture, and induced tumor regression in a patient-derived xenograft (PDX) model (PMID: 40018846). 40018846
KIT V559D KIT V654A Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT V559D and KIT V654A in an vitro assay (PMID: 40018846). 40018846
KIT K642E gastrointestinal stromal tumor predicted - sensitive IDRX-42 Preclinical - Pdx Actionable In a preclinical study, IDRX-42 treatment inhibited mitosis and decreased tumor growth in a cell line xenograft model and a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT K642E (PMID: 37223931). 37223931
KIT V560_Y578del KIT V654A gastrointestinal stromal tumor sensitive IDRX-42 Preclinical - Pdx & cell culture Actionable In a preclinical study, IDRX-42 inhibited viability of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del and KIT V654A in culture, and resulted in tumor shrinkage in a cell line xenograft model and a complete response in a patient-derived xenograft (PDX) model (PMID: 40018846). 40018846
KIT V559A Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT V559A in an vitro assay (PMID: 40018846). 40018846
KIT exon9 gastrointestinal stromal tumor predicted - sensitive IDRX-42 Phase I Actionable In a Phase I trial, IDRX-42 treatment demonstrated safety and resulted in 9 partial responses among 39 evaluable patients with gastrointestinal stromal tumors harboring a KIT exon 11 (n=27), exon 9 (n=13), or exon 8 (n=2) mutation with a clinical benefit rate of 71% overall and 100% as second-line treatment (J Clin Oncol 42, 2024 (suppl 16; abstr 11501); NCT05489237). detail...
KIT A502_Y503dup gastrointestinal stromal tumor predicted - sensitive IDRX-42 Preclinical - Pdx Actionable In a preclinical study, IDRX-42 treatment inhibited mitosis and decreased tumor growth in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT A502_Y503dup (PMID: 37223931). 37223931
KIT K642E Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT K642E in an vitro assay (PMID: 40018846). 40018846
KIT exon11 gastrointestinal stromal tumor predicted - sensitive IDRX-42 Phase I Actionable In a Phase I trial, IDRX-42 treatment demonstrated safety and resulted in 9 partial responses among 39 evaluable patients with gastrointestinal stromal tumor harboring a KIT exon 11 (n=27), exon 9 (n=13), or exon 8 (n=2) mutation with a clinical benefit rate of 71% overall and 100% as second-line treatment (J Clin Oncol 42, 2024 (suppl 16; abstr 11501); NCT05489237). detail...
KIT V560G KIT N822K Advanced Solid Tumor predicted - sensitive IDRX-42 Preclinical - Biochemical Actionable In a preclinical study, IDRX-42 inhibited kinase activity of KIT V560G and KIT N822K in an vitro assay (PMID: 40018846). 40018846
KIT N822K acute myeloid leukemia sensitive IDRX-42 Preclinical - Cell line xenograft Actionable In a preclinical study, IDRX-42 inhibited viability of an acute myeloid leukemia cell line harboring KIT N822K in culture, and induced tumor regression in a cell line xenograft model (PMID: 40018846). 40018846
KIT W557_K558del KIT Y823D gastrointestinal stromal tumor sensitive IDRX-42 Preclinical - Pdx Actionable In a preclinical study, IDRX-42 treatment resulted in tumor shrinkage in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_K558del and KIT Y823D (PMID: 40018846). 40018846

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05489237 Phase I IDRX-42 A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1] Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 3


Additional content available in Icon for CKB-BoostCKB BOOST